التفاصيل البيبلوغرافية
| العنوان: |
The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. |
| المؤلفون: |
Jamnagerwalla, Juzar, Howard, Lauren E., Vidal, Adriana C., Moreira, Daniel M., Castro-Santamaria, Ramiro, Andriole, Gerald L., Freedland, Stephen J. |
| المصدر: |
Journal of Urology; Sep2016, Vol. 196 Issue 3, p715-720, 6p |
| مصطلحات موضوعية: |
PHOSPHODIESTERASE-5 inhibitors, PROSTATE cancer risk factors, TREATMENT of sexual dysfunction, IMPOTENCE, CHEMOPREVENTION, PROSTATE-specific antigen |
| مستخلص: |
Purpose Despite routine use of phosphodiesterase type 5 inhibitor to treat erectile dysfunction the role in prostate cancer chemoprevention remains unclear. Only a few studies have explored the link between phosphodiesterase type 5 inhibitor use and prostate cancer. We tested the association between phosphodiesterase type 5 inhibitor and prostate cancer risk in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial. Materials and Methods REDUCE was a 4-year multicenter study testing the effect of daily dutasteride on prostate cancer risk in men with prostate specific antigen 2.5 to 10.0 ng/ml and negative biopsy who underwent study mandated biopsies at 2 and 4 years. The association of phosphodiesterase type 5 inhibitor with overall prostate cancer risk and disease grade (Gleason 2-6 and 7-10) was examined using adjusted logistic and multinomial regression analysis. Secondary analysis was performed to explore the association between phosphodiesterase type 5 inhibitor and prostate cancer risk in North American men, given the significantly higher use of phosphodiesterase type 5 inhibitor in these subjects. Results Phosphodiesterase type 5 inhibitor was not associated with prostate cancer diagnosis (OR 0.90, 95% CI 0.68–1.20, p = 0.476), low grade disease (OR 0.93, 95% CI 0.67–1.27, p = 0.632) or high grade disease (OR 0.85, 95% CI 0.51–1.39, p = 0.508). An inverse trend was seen between phosphodiesterase type 5 inhibitor and prostate cancer diagnosis in North American men but this was not statistically significant (OR 0.67, 95% CI 0.42–1.07, p = 0.091). Conclusions Phosphodiesterase type 5 inhibitor use was not associated with decreased prostate cancer diagnoses on post-hoc analysis of REDUCE. In North American men, who had much higher baseline use of phosphodiesterase type 5 inhibitor, this treatment was associated with an inverse trend of prostate cancer diagnosis that approached but did not reach statistical significance. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Urology is the property of Wolters Kluwer UK and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Supplemental Index |
